This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICM's New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland

"The process of developing and generating a new drug or treatment normally takes up to three years, and costs have nearly quadrupled in the past 15 years," said Prof. Marek Niezgodka, Director of ICM. "With Nostromo, we expect to increase the simulation speed which will bring us much closer to the era of "personalized medicine," when preventative approaches can be tailored to a specific condition."

Nostromo currently ranks N 143 on the Top500.org list and N 9 on Green500.org. The system has already been installed by IBM Poland and Qumak SA, IBM's Business Partner.

"IBM delivered the most powerful single architecture supercomputer for the ICM of Poland.  Nostromo is able to process up to 16 TB of Big Data per one sequence by running simulations at the speed of 210 TFLOPS," said Ales Bartunek, Country General Manager, IBM Poland and Baltics. "We are confident that the POWER based Blue Gene/Q has the potential to save years of research and help scientists take healthcare in Poland to the next level."

About Nostromo

The IBM Blue Gene/Q system, based on POWER architecture, currently ranks N 143 on the Top500.org list and N 9 on the Green500.org. It runs at 209.7 trillion operations per second (TFLOPS). Its ability to process Big Data is instrumental for the faster isolation and analysis of genes and proteins, responsible for the most common chronic lifestyle diseases. It can also be used to simulate new drug development. The supercomputing's drug modeling, integrates mathematics, physics, chemistry and biology with advanced, high performance computing and engineering and has the potential to significantly reduce a new drug's time to market by developing new procedures of drug design.

Blue Gene/Q (BG/Q) is the next evolutionary waypoint on IBM's HPC leadership roadmap to ultra-scalability and ultra-reliability in a power-efficient, space-saving platform for the most demanding grand challenge computational science applications. It is the next logical step towards developing technologies and architectures for exascale capable computing systems.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs